The first human mutations in GATA6 were described in a cohort of patients with persistent truncus arteriosus, and the phenotypic spectrum has expanded since then. This study underscores the broad phenotypic spectrum by presenting two patients with de novo GATA6 mutations, both exhibiting complex cardiac defects, pancreatic, and other abnormalities. Furthermore, we provided a detailed overview of all published human genetic variation in/near GATA6 published to date and the associated phenotypes (n = 78). We conclude that the most common phenotypes associated with a mutation in GATA6 were structural cardiac and pancreatic abnormalities, with a penetrance of 87 and 60%, respectively. Other common malformations were gallbladder agenesis, congenital diaphragmatic hernia, and neurocognitive abnormalities, mostly developmental delay. Fifty-eight percent of the mutations were de novo, and these patients more often had an anomaly of intracardiac connections, an anomaly of the great arteries, and hypothyroidism, compared with those with inherited mutations. Functional studies mostly support loss-of-function as the pathophysiological mechanism. In conclusion, GATA6 mutations give a wide range of phenotypic defects, most frequently malformations of the heart and pancreas. This highlights the importance of detailed clinical evaluation of identified carriers to evaluate their full phenotypic spectrum.
| INTRODUCTION
Congenital heart disease (CHD) consists of structural abnormalities of the heart and/or the intrathoracic blood vessels and is the most common birth defect worldwide with an estimated prevalence of around 1% (van der Linde et al., 2011) . Although the heritable nature of CHD is well-demonstrated (yen et al., 2009) , the underlying genetic causes are incompletely understood. Aneuploidies and large copy number variations have been found in CHD patients, but usually in those with wellrecognized clinical syndromes, like Down syndrome and DiGeorge syndrome (Fahed, Gelb, Seidman, & Seidman, 2013; . The use of linkage analysis, positional cloning, sequencing of candidate genes, and next-generation sequencing (including whole-exome and whole-genome sequencing) has led to the implication of a large number of genes in CHD, highlighting its high genetic heterogeneity (Fahed et al., 2013; . A significant subset of these genes encodes cardiac transcription (co)factors (McCulley & Black, 2012) , among which are the GATA transcription factors. Of this family of six zinc finger nuclear transcription factors, GATA4, 5, and 6 are important regulators of gene expression in developing organs derived from endoderm and mesoderm (Molkentin, 2000) , including the heart, organs of the digestive and urogenital system, and the brain (Nemer & Nemer, 2003) . GATA factors owe their name to the DNA sequence (5 0 -(T/A)GATA(A/G)-3 0 ) in enhancer and promotor regions of target genes they bind to (Brewer & Pizzey, 2006) . The expression of GATA6 has a distinct spatiotemporal pattern shows overlap with that of GATA4 and 5 in the heart (Xin et al., 2006) and also in other tissues (Nemer & Nemer, 2003) . Although GATA6-knockout mice all die before heart formation (E6.5-E7.5), due to defects in the early endoderm formation (Morrisey et al., 1998) , conditional inactivation of GATA6 in murine neuralcrest-derived vascular smooth-muscle cells resulted in a spectrum of cardiac outflow tract defects (64% persistent truncus arteriosus [PTA] and 36% double outlet right ventricle [DORV]; Lepore et al., 2006) , underscoring the importance of GATA6 in normal heart development.
The initial discovery of human GATA6 mutations was in individuals with a severe CHD, namely PTA (Kodo et al., 2009 ). However, shortly after, GATA6 mutations were also found to be an important cause of pancreatic agenesis (Allen et al., 2011) . Indeed, GATA6 is initially expressed in the early pancreatic epithelium (together with GATA4) and later becomes restricted to the endocrine cells of the pancreas (Decker, Goldman, Grasch, & Sussel, 2006; Ketola et al., 2004) . In addition, mice conditionally overexpressing a Gata6/4-Engrailed fusion protein designed to function as a dominant negative transcriptional repressor show a strong reduction in pancreatic tissue volume (Decker et al., 2006) . This model recapitulates the pancreatic phenotype in humans.
We present two patients, both with a de novo GATA6 mutation, who illustrate the phenotypic heterogeneity associated with mutations in this gene. In addition, we provide an overview of all the GATA6 mutations reported in the literature (n = 78) to date and explore genotype-phenotype correlations.
| MATERIALS AND METHODS

| Clinical evaluation
Patient 1 and Patient 2 were recruited at two academic hospitals in the Netherlands (Amsterdam University Medical Centre and Leiden University Medical Centre, respectively). Of note, Patient 2 was previously included in an international neonatal diabetes cohort that was tested for mutations in GATA6 (De Franco et al., 2013) . Detailed phenotypic data were obtained by medical history interviews and from clinical records. Written informed consent was obtained from the patient and/or parents. The study was approved by the appropriate medical ethical committee of the two hospitals.
| Genetic testing
| Patient 1
Whole-exome sequencing was performed in Patient 1 and his unaffected parents on DNA isolated from peripheral blood leucocytes at the Beijing Genomics Institute (Shenzhen, China). Details on the sequencing process and bioinformatics pipeline can be found in the Supporting Information Methods section. Based on the pedigree and family history, de novo variants were prioritized. We also explored the option of autosomal recessive and autosomal X-linked inheritance. All the analysis was carried out in the software program R (R version 3.4.0; R core team, 2017).
| Patient 2
Detailed description on the molecular genetic analysis of Patient 2 has been previously reported (De Franco et al., 2013) . In brief, mutations in the genes ABCC8, KCNJ11, and INS and chromosome 6q24 abnormalities had been excluded before screening the coding and flanking sequence of GATA6 using Sanger sequencing. Subsequently, the de novo state of the identified GATA6 mutation was confirmed by microsatellite analysis.
| Literature search
We searched in PubMed using the terms "GATA6 Transcription Factor"[Mesh] AND "GATA6 protein, human" [Supporting Information Concept] . This resulted in 178 items. Suitable papers were selected based on the abstract. Inclusion criteria were: human subjects with specified GATA6 mutations (all ethnicities and phenotypes) where the full text was available. Large (case-control) cohorts as well as case reports were selected. We checked the references in these papers and screened papers that cited the included papers. Additionally, large CHD cohorts (Homsy et al., 2015; Jin et al., 2017; Sifrim et al., 2016; Zaidi et al., 2013) were checked for patients with GATA6 mutations.
Lastly, we checked curated databases (e.g., Clinvar and OMIM) to identify any missing mutations. We included all rare variants with (minor allele frequency < 0.001) and/or those not found in ethnically matched healthy controls (in case-control studies). Patients with trisomy 18 were excluded. Congenital cardiac defects were classified based on the International Pediatric and Congenital Cardiac Code (Franklin et al., 2017) . Statistical comparisons were performed using Fisher's exact test, and Bonferroni corrected p values were used for determination of statistical significance (p = .05/n tests). In addition, he was diagnosed with diabetes mellitus (DM) Type I during young adulthood. Discovery of the GATA6 mutation initiated a renewed examination of the etiology of the DM and revealed pancreatic hypoplasia (Figure 1i ,j). Other abnormalities are described in Table 1 .
| Genetic findings
After applying the described filtering steps (see Supporting Information Methods section), eight variants were left that fitted a de novo inheritance (seven single nucleotide variants [SNVs] and one deletion; Table S1 ). After visual inspection of the Binary Alignment Map files, four variants were found in (one of) the parents and therefore discarded as de novo. The four remaining variants were tested by Sanger sequencing in the patient and his parents, two of which were confirmed to be truly de novo, namely EGR3 p.(Glu347Asp) (NM_004430) and GATA6 p.(Arg456His) (NM_005257). EGR3, early growth response 3, is a zinc-finger transcription factor, involved in proper muscle spindle development and knock-out mice show a severe neurological and musculoskeletal phenotype including tremor, ataxia, abnormal gait, and scoliosis (Tourtellotte & Milbrandt, 1998 ), but no cardiac or pancreatic phenotype was described. Thus far, this gene was not implicated in human disease.
Conversely, GATA6 was clearly a strong candidate based on function and literature. The same mutation, p.(Arg456His) was previously identified in a patient with CHD, and other mutations at the same amino acid location, namely p.(Arg456Cys) and p.(Arg456Gly), were identified in another five patients (for phenotypes see Table S2 ; Allen et al., 2011; Jin et al., 2017; Sanyoura et al., 2018; Yu et al., 2014) . Although the GATA6-p.
(Arg456His) was not tested functionally, the GATA6-p. (Arg456Cys) showed significantly decreased transcriptional activity on the WNT2 promotor (Allen et al., 2011) . The deleteriousness of the variant found in T A B L E 1 Overview of clinical phenotypes of patient 1 and patient 2 3.3 | Human GATA6 mutations in the literature Thirty-eight papers described patients with potentially pathogenic variants in GATA6 (Table S2 ). Focusing on exonic SNVs, small insertion/deletions, and splice site variants, there were 68 mutations in 85 independent probands (including the two patients in this manuscript). In 28 probands, the mode of inheritance was (or could) not (be) tested. In the remaining 57 probands, the variant arose de novo in 58% (33 of 57). Interestingly, in three cases, the inherited mutation was found mosaic in the parent (the mother in all cases). Eighty-five percent of these mutations were absent in >130,000 individuals in gnomAD (Lek et al., 2016) and the remaining ones are present at a very low frequency, which fits with the low prevalence of the phenotypes related to this gene.
In total, there were data available on 135 GATA6 mutation carriers pancreatic phenotype, there was data available for 91%, and 60% of them had a pancreatic phenotype. There was no statistical difference in the penetrance of these phenotypes between mutation type (missense vs. loss-of-function; LoF).
For 27 mutations, their functional consequence was investigated by measuring the transcriptional activity of GATA6 on several different target genes (e.g., ANF, BNP, and αMHC) by a luciferase assay in vitro (Table S2 ). Most of the tested GATA6 mutants (20 of 27, 74%) demonstrated a reduction in transcriptional activity of the GATA6 target genes, compared to wild-type GATA6. For the remaining seven mutations, there was either an increase or no effect observed in transcriptional activity.
We stratified the patients according to inheritance (de novo vs. inherited) and saw that patients with a de novo mutation more often had an anomaly of intracardiac connections (mainly PTA and transposition of the great arteries [TGA]) and also an anomaly of the great arteries (mainly patent ductus arteriosus), than those with an inherited mutation (p = .004 and p = .003, respectively).
When stratifying patients according to the type of mutation (missense vs. LoF mutation), we did not observe any statistically significant differences (Table S4 ). For pancreatic abnormalities and in the different other categories of extracardiac malformations (see Figure 3 for the categories), we did not observe significant differences at the Bonferroni-corrected p value threshold, when stratifying patients according to inheritance mode or type of mutation (data not shown).
However, endocrine abnormalities (in all cases hypothyroidism) did seem to be present more often in patients with a de novo mutation and in those with a missense mutation (p = .03 and p = .01, respectively).
Five mutations were found in more than one independent proband (p.(Glu142Lys), p.(Ser184Asn), p.(Arg456Cys), p.(Arg456His) and p.(Lys502fs)) and one of these, p.(Ser184Asn), was even found in 12 independent probands. It is located in the transcriptional activation domain of the protein, essential for transcriptional activity (Brewer & Pizzey, 2006) . Ten of these 12 probands exhibited outflow tract defects (tetralogy of Fallot [TOF], DORV, and TGA). Unfortunately, information on extracardiac features was not available in any of these 12 patients.
Topologically, the GATA6 protein has at least three functional domains: a transcriptional activation domain essential for its transcriptional activity and two zinc finger domains required for DNA sequence recognition and binding to the consensus motif (Brewer & Pizzey, 2006) . We plotted all mutations on a schematic diagram of the GATA6 protein ( Figure 3) . Most mutations were located within the functional domains of GATA6 (48 of 68; 71%). Furthermore, missense mutations were more often located in the zinc finger domains, whereas LoF mutations were more often located in the transcriptional activation domain (p = .01 and p = .04, respectively). There were no statistically significant differences in presence or type of cardiac or extracardiac phenotypes between mutations located inside and outside of the functional domains (inside vs. outside all functional domains; data not shown).
Besides the 68 exonic and splice site GATA6 mutations, other genetic variation affecting GATA6 was described. These involved mutations in the promotor region of GATA6 (n = 4 probands) or chromosomal aberrations (n = 4 probands; 3 duplications, and 1 deletion).
Furthermore, somatic mutations (in right ventricular outflow tract tissue) were described in two TOF patients. The phenotypic characteristics of carriers of these genetic variants can be found in Table S2 . In most of these patients, the pancreatic defects were not assessed and the cardiac phenotypes were diverse. Of note, the chromosomal aberrations involved multiple genes and the role of GATA6 was therefore difficult to assess. Thus, the interpretation of the causality of these categories of genetic variation remains challenging.
| DISCUSSION
We have presented two cases here with de novo GATA6 mutations leading to a complex cardiac phenotype, pancreatic malformations, and other extracardiac abnormalities. Both patients add to the broad phenotypic spectrum of GATA6 mutations and exhibit malformations that distinguish them from the other described patients. Specifically, Patient 1 had a very complex and rare cardiac phenotype, never described before in GATA6 mutation-positive individuals (superiorinferior ventricles, VSD and PS), and, moreover, the discovery of the GATA6 mutation has led to identifying the cause of his DM (i.e., pancreatic hypoplasia). Patient 2 had a rare extracardiac abnormality, namely PLE, only described in one other GATA6 positive patient (McMillan et al., 2016) . Although PLE is a well-known complication of the Fontan procedure (Mertens, Hagler, Sauer, Somerville, & Gewillig, 1998) , this patient had undergone a Rastelli procedure and moreover, the central venous pressure was low when measured with cardiac catheterization during one of the PLE episodes. Therefore, we did not consider PLE here as secondary to the cardiac surgery but as part of the GATA6 phenotypic spectrum. We have further provided an overview of all the phenotypes associated with human GATA6 mutations described in the literature to date.
Human GATA6 mutations were first described in patients with PTA (Kodo et al., 2009) but have later been shown to give rise to not only a variety of other cardiovascular malformations but also extracardiac abnormalities (mainly pancreatic malformations). There is both clear interfamilial and intrafamilial phenotypic variability, most likely due to differences in genetic background, environmental factors, and epigenetic factors. We found cardiac structural abnormalities and pancreatic abnormalities to be the phenotypes most commonly associated with GATA6 mutations. The penetrance of the cardiac phenotype was higher than the penetrance of the pancreatic phenotype (87% vs. 60%), however, the absolute numbers are low and the percentage of pancreatic disease is high enough to warrant screening in all carriers. Other common described extracardiac features included gallbladder agenesis, congenital diaphragmatic hernia, and developmental delay. The mode of inheritance was de novo in 58% of probands, and our stratified analysis showed that patients with a de novo mutation have anomalies of intracardiac connections and the great arteries more often and also exhibit more hypothyroidism than those with an inherited mutation. One possible explanation for this could be that patients with a severe CHD did not reach a reproductive age before the modern surgical era, and thus this group of patients is more likely to carry a de novo mutation. Performing detailed clinical screening in GATA6 positive patients will help to improve genotype-phenotype correlations in the future.
The mechanism by which mutations in GATA6 lead to the associated phenotypes is still not completely elucidated. The downstream targets of GATA6 include the genes encoding atrial natriuretic factor, brain natriuretic peptide, a-myosin heavy chain, hepatocyte nuclear factor 4 alpha, and other genes (Morrisey et al., 1998; Rémond et al., 2011 ) required for normal cardiac and pancreatic development. The leading hypothesis is a LoF mechanism due to haploinsufficiency.
Seventy-four percent of the GATA6 mutations described in the literature, where transcriptional activity was investigated, lead to decreased transcriptional activity on target genes. In addition, over 50% of the described GATA6 mutations fall in the category LoF (i.e., frameshift mutations with a premature stop, nonsense mutation or splice site mutations); whereas in the gnomAD database (with >130,000 individuals), only four such variants could be found (Lek et al., 2016) .
Although this further supports a haploinsufficiency mechanism, it remains striking that heterozygous GATA6 null mice have no phenotype (Morrisey et al., 1998) . Moreover, Kodo et al. showed that cotransfecting the same amount of wild-type and p.(Glu486fs) mutant GATA6 in HeLa cells had a stronger inhibitory transcriptional effect on downstream target genes, compared to half of the wild-type alone, which could suggest a dominant negative mechanism (Kodo et al., 2009 ).
Among all described GATA6 positive individuals, there are in total 25 patients from 12 independent families with different mutations reported with AF, the most common arrhythmia in the general population (Anderson et al., 2013) . Nine of these patients (36%) have AF accompanied by a structural defect (ASD, VSD, or dilated cardiomyopathy), which might be the substrate for AF in these cases. However, there are also 16 patients with AF in the absence of a structural cardiac defect. This latter category of AF patients is relatively younger compared to the general AF population (mean age 39, range 14-61, vs. 75 years [Feinberg, Blackshear, Laupacis, Kronmal, & Hart, 1995] ).
The exact pathophysiology remains unclear, and although half of the tested GATA6 variants associated with AF showed decreased transcriptional activity on downstream target genes, supporting a LoF mechanism, there were also three mutations (p.(Pro91Ser), p.(Ala177Thr), and p.(Arg585Leu)) with increased transcriptional activity, suggesting a gain-of-function mechanism. GATA6 was not identified in the latest AF genome-wide association study (GWAS) including >1 million people (Nielsen et al., 2018) but interestingly did show up as a candidate gene in a GWAS on resting heart rate (Eppinga et al., 2016) , suggestive of a possible role in cardiac electrical function.
The diagnostic yield of screening for GATA6 strongly depends upon the selected phenotype; in isolated CHD cohorts (Homsy et al., 2015; Jin et al., 2017; Kodo et al., 2009; Kodo et al., 2012; Lin et al., 2010; Maitra, Koenig, Srivastava, & Garg, 2010; J. Wang et al., 2012;  X. Wang et al., 2014; Zhang et al., 2018; Zheng et al., 2012) , the yield was around~0.5%, whereas in cohorts selected on pancreatic abnormalities (pancreatic agenesis or neonatal DM; Allen et al., 2011; De Franco et al., 2013; Gong et al., 2013; Sanyoura et al., 2018) , the mutation yield was~11%. Allen et al. showed that 93% of the GATA6 mutation carriers have a cardiac defect versus none of the GATA6 mutation-negative patients (Allen et al., 2011) . We therefore speculate that the yield will be the highest in patients with a combination of cardiac and pancreatic malformations.
An important limitation in our effort to establish an overview of the full phenotypic spectrum of GATA6 is that most GATA6 mutationpositive individuals were identified by screening large cohorts where patients either had CHD and/or pancreatic abnormalities. Detailed clinical evaluation to detect other associated features was missing in those cases. Moreover, most CHD cohorts selected only cases in whom extracardiac anomalies were excluded (i.e., isolated CHD cases), causing bias due to selective inclusion. This might explain the overrepresentation of cases with isolated cardiac phenotypes. As it is impossible to determine how extensive the clinical evaluation was in each patient, when there was no mention of cardiac, pancreatic, or other extracardiac phenotypes (unless specifically stated otherwise), we scored these data as unavailable. For family members we assumed that, if there was a cardiac, pancreatic or other extracardiac phenotype described in the proband, this was also checked in carriers from the same family. In the latter case, if an abnormality was not mentioned in these family members, we scored this data as normal. Nonetheless, as far as we could determine, this is the most comprehensive overview of GATA6 mutations and related phenotypes to date. It would be interesting to see the yield of GATA6 testing in a prospective unbiased pediatric cohort with a broad and unselected phenotype, to explore the exact phenotypic spectrum of GATA6.
We hope this study will contribute to increased awareness among treating physicians of patients with a combination of cardiac and pancreatic malformations/DM (potentially in the presence of other abnormalities) about the possibility of a GATA6 mutation. Subsequently, these patients should be referred to the clinical geneticist for diagnostic testing. Conversely, patients in whom a GATA6 pathogenic mutation has been identified should undergo extensive clinical testing, in order to assess the full disease spectrum in these individuals. This will also hopefully contribute to a better estimation of the mutational yield and to clear genotype-phenotype correlations.
